Charles River articles

The research summarized in this whitepaper provides a number of examples of how ALZET® pumps offer a superior pre-clinical drug dosing option for the delivery of a wide array of anti-cancer agents, including small molecules, immunotherapies, radiotherapies, combination treatments, and novel drug entities.

This whitepaper also explores how ALZET® pumps have been used to successfully test treatments for cancer-associated syndromes and treatment-related side effects.

As the complexity of advanced therapies continues to grow, more data is needed to establish a drug’s mode of action, efficacy, and long-term safety. It’s no wonder, then, that big data is fueling the drive for tomorrow’s therapies. However, most developers lack the in-house capabilities to produce it and/or the expertise to evaluate it.

Charles River has created a complete solution for clients whose programs depend on harnessing big data. Through a new partnership wi

Charles River is pleased to announce that the 5^th Annual Viral Safety and Viral Clearance Summit will take place at the Hyatt Centric Fisherman`s Wharf in San Francisco, California on October 6 – 7, 2020.

More than 110 attendees and speakers joined us for last year`s event, which was held at the same venue. They represented various industries including regulatory, service, and technology, as well as representatives from FDA/CBER.

A

We`ve added over 125 new datasets to our Cancer Model Database. It provides access to a comprehensive collection of well-established tumor models for early-stage oncology research and increases their translational capabilities to the clinic.

The update adds new patient-derived xenograft (PDX) models for several cancer types, including anal, colon, kidney, renal, and leukemia. Additionally, this update provide